Tereza Martinu
Lung transplant respirologist and clinician-scientist whose research addresses immunological and cellular mechanisms of CLAD.
As of . Primary source: UHN Research profile.
Summary
According to the Practical Platform and University of Toronto profiles, Tereza Martinu (MD, MHS) is a lung transplant respirologist and clinician-scientist with the Toronto Lung Transplant Program, an Associate Professor at the University of Toronto and the program's Director of Research. Her stated focus is the discovery of mechanisms, biomarkers and therapeutics for CLAD. She is a co-author of the 2019 ISHLT CLAD consensus report.
Details
- role
- Lung transplant respirologist and clinician-scientist; Director of Research, Toronto Lung Transplant Program; Associate Professor (University of Toronto)
- affiliation
- Toronto Lung Transplant Program, University Health Network; University of Toronto
Sources and links
Related
Links from this record
- member of: Toronto Lung Transplant Program (University Health Network)
- coauthor: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment: A consensus report from the Pulmonary Council of the ISHLT
- author: Identification and characterization of inflammatory LILR and fibrotic SPP1 macrophages in chronic lung allograft dysfunction
- author: Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
- author: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- author: Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry
- author: The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction
- author: Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction
- author: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- author: Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome
- author: Donor and recipient human leukocyte antigen-G polymorphisms modulate the risk of adverse immunologic events following lung transplantation
- author: Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system
- author: Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways
- author: Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study
- author: Center variability in the prognostic value of a cumulative acute cellular rejection "A-score" for long-term lung transplant outcomes
- author: Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement
- author: Lung microbiome quantification and bacterial density as prognostic markers in lung transplantation
- author: Intra-subject variability in oscillometry correlates with acute rejection and CLAD post-lung transplant
Linked from (derived)
- coauthor: The CD8+ T cell content of transbronchial biopsies from patients with a first episode of clinically stable grade A1 cellular rejection is associated with future chronic lung allograft dysfunction
- coauthor: Center variability in the prognostic value of a cumulative acute cellular rejection "A-score" for long-term lung transplant outcomes
- coauthor: Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system
- coauthor: Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways
- author (last author, corresponding): CLAD: translating basic science to clinical practice
- coauthor: Eosinophils in transbronchial biopsies: a predictor of chronic lung allograft dysfunction and reduced survival after lung transplantation — a retrospective single‐center cohort study.
- coauthor: Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion
- author: Identification and characterization of inflammatory LILR and fibrotic SPP1 macrophages in chronic lung allograft dysfunction
- coauthor: Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement
- coauthor: Quantitative chest CT for subtyping chronic lung allograft dysfunction and its association with survival.
- author (last author): Distinct fibrotic, epithelial and immune transcriptomic programs in phenotypes of chronic lung allograft dysfunction
- coauthor: Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients-a single-center retrospective cohort study
- coauthor: Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system
- coauthor: The impact of first untreated subclinical minimal acute rejection on risk for chronic lung allograft dysfunction or death after lung transplantation.
- coauthor: Pulmonary epithelial markers in phenotypes of chronic lung allograft dysfunction
- coauthor: Bronchoalveolar lavage cytokine-based risk stratification of clinically-stable lung transplant recipients with undefined rejection: Further insights from a follow-up investigation
- author: Spectrum of chronic lung allograft pathology in a mouse minor-mismatched orthotopic lung transplant model
- coauthor: Local intragraft humoral immune responses in chronic lung allograft dysfunction.
- coauthor: Interferon-stimulated and metallothionein-expressing macrophages are associated with acute and chronic allograft dysfunction after lung transplantation
- coauthor: Emergence of a senescent and inflammatory pulmonary CD4+ T cell population prior to lung allograft failure
- coauthor: Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome
- coauthor: Oesophageal stasis is a risk factor for chronic lung allograft dysfunction and allograft failure in lung transplant recipients.
- coauthor: Airway pepsinogen A4 identifies lung transplant recipients with microaspiration and predicts chronic lung allograft dysfunction
- coauthor: Spectrum of chronic lung allograft dysfunction pathology in human lung transplantation.
- coauthor: Detailed cellular and spatial characterization of chronic lung allograft dysfunction using imaging mass cytometry
- coauthor: Donor and recipient human leukocyte antigen-G polymorphisms modulate the risk of adverse immunologic events following lung transplantation
- coauthor: Reduced lung fluid club cell secretory protein informs chronic lung allograft dysfunction risk
- coauthor: Lung microbiome quantification and bacterial density as prognostic markers in lung transplantation
- coauthor: De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation
- coauthor: Early posttransplant reductions in club cell secretory protein associate with future risk for chronic allograft dysfunction in lung recipients: results from a multicenter study
- coauthor: Prognosis and Risks for Probable Chronic Lung Allograft Dysfunction: A Prospective Multicenter Study
- coauthor: Intra-subject variability in oscillometry correlates with acute rejection and CLAD post-lung transplant
- coauthor: Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
- coauthor: Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment: A consensus report from the Pulmonary Council of the ISHLT
- coauthor: Humoral immunity to lung antigens early post-transplant confers risk for chronic lung allograft dysfunction.
- member: Toronto Lung Transplant Program (University Health Network)
Known gaps in this record
- current funding
- ORCID
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.